Listing 3 - Actual negotiations

Indication:

Eosinophilic Esophagitis (Maintenance)

Indication:

Eosinophilic Esophagitis (Induction)

Indication:

Cystic Fibrosis, F508del CFTR mutation in patients aged 6 years and older

Indication:

Metastatic colorectal cancer (mCRC) in patients with a BRAF V600E mutation, as detected by a validated test, after prior therapy (in combination with cetuximab)

Indication:

Unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test, (encorafenib and binimetinib in combination)

Indication:

Asthma

Indication:

Neuromyelitis optica spectrum disorder (NMOSD)

Indication:

Chronic Obstructive Pulmonary Disease (COPD)

Indication:

Acute myeloid leukemia (AML), Maintenance therapy in adult patients who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation (HSCT)

Indication:

Diabetes Mellitus, Type 1 & 2